Rockwell Medical (NASDAQ:RMTI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Rockwell Medical (NASDAQ:RMTIGet Rating) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Separately, Zacks Investment Research raised Rockwell Medical from a hold rating to a buy rating and set a $2.25 price target for the company in a report on Friday.

NASDAQ:RMTI opened at $1.67 on Friday. The company has a debt-to-equity ratio of 5.21, a current ratio of 1.27 and a quick ratio of 1.49. The business has a fifty day simple moving average of $4.19 and a two-hundred day simple moving average of $4.36. Rockwell Medical has a 1 year low of $1.62 and a 1 year high of $11.66.

Rockwell Medical (NASDAQ:RMTIGet Rating) last released its earnings results on Thursday, May 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.15. Rockwell Medical had a negative return on equity of 474.88% and a negative net margin of 51.27%. The business had revenue of $16.12 million during the quarter, compared to the consensus estimate of $18.80 million. During the same period last year, the business posted ($0.08) earnings per share. On average, equities analysts predict that Rockwell Medical will post -3.74 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new position in shares of Rockwell Medical in the first quarter worth $57,000. Metropolitan Life Insurance Co NY bought a new stake in Rockwell Medical during the first quarter valued at $106,000. Renaissance Technologies LLC boosted its stake in Rockwell Medical by 81.1% during the fourth quarter. Renaissance Technologies LLC now owns 225,534 shares of the company’s stock valued at $92,000 after buying an additional 101,000 shares during the period. Verdence Capital Advisors LLC boosted its stake in Rockwell Medical by 25.1% during the fourth quarter. Verdence Capital Advisors LLC now owns 443,545 shares of the company’s stock valued at $182,000 after buying an additional 88,980 shares during the period. Finally, Perkins Capital Management Inc. boosted its stake in Rockwell Medical by 34.5% during the fourth quarter. Perkins Capital Management Inc. now owns 2,957,025 shares of the company’s stock valued at $1,212,000 after buying an additional 758,400 shares during the period. 27.88% of the stock is owned by hedge funds and other institutional investors.

About Rockwell Medical (Get Rating)

Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.

Recommended Stories

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.